Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX3232 in Early-Stage Parkinson's Disease
NCT06556173Phase 2Completed
- Sponsor
- Zomagen Biosciences
- Start
- Aug 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of VTX3232 in Parkinson's disease (PD), sponsored by Zomagen Biosciences. Started Aug 2024; status: completed.
02
Drugs
VTX3232
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06556173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06556173.